MX2007006104A - Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol. - Google Patents

Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol.

Info

Publication number
MX2007006104A
MX2007006104A MX2007006104A MX2007006104A MX2007006104A MX 2007006104 A MX2007006104 A MX 2007006104A MX 2007006104 A MX2007006104 A MX 2007006104A MX 2007006104 A MX2007006104 A MX 2007006104A MX 2007006104 A MX2007006104 A MX 2007006104A
Authority
MX
Mexico
Prior art keywords
trans
tetrahydrocannabinol
methods
tetrahydrocannabinoi
composition
Prior art date
Application number
MX2007006104A
Other languages
English (en)
Inventor
Gennady A Nisnevich
Boris Pertsikov
Boris Tishin
Igor Rukhman
Arie L Gutman
Marina Etinger
Irina Fedotev
Ram Khanolkar
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007006104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2007006104A publication Critical patent/MX2007006104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)

Abstract

Metodos para producir trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol son descritos en este documento. En una modalidad, una composicion trans-(-)-?9-tetrahidrocanabinol es preparada al permitir que una composicion que comprende (??)-?9-tetrahidrocanabinol se separe en una fase quiral estacionaria para proporcionar una composicion trans-(-)-?9-tetrahidrocanabinol que comprende al menos alrededor de un 99% en peso de trans-(-)-?9-tetrahidrocanabinol basado en la cantidad total de trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol. La invencion tambien se refiere a metodos para tratar o prevenir una condicion tal como dolor, comprendiendo la administracion a un paciente, que necesite del mismo, una cantidad efectiva de un trans-(-)-?9-tetrahidrocanabino l teniendo una pureza de al menos alrededor de 98%, basado en el peso total de canabinoides.
MX2007006104A 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol. MX2007006104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22
PCT/EP2005/012378 WO2006053766A1 (en) 2004-11-22 2005-11-18 Methods for purifying trans-(-)-δ9-tetrahydrocannabinol and trans-(+)-δ9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
MX2007006104A true MX2007006104A (es) 2007-07-11

Family

ID=35789123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006104A MX2007006104A (es) 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol.

Country Status (31)

Country Link
US (6) US8383842B2 (es)
EP (3) EP1824475B1 (es)
JP (3) JP4995728B2 (es)
KR (1) KR100919719B1 (es)
CN (2) CN102151259A (es)
AR (1) AR054989A1 (es)
AT (1) ATE500824T1 (es)
AU (2) AU2005305944B2 (es)
BR (1) BRPI0519803A2 (es)
CA (2) CA2921590C (es)
CY (1) CY1111471T1 (es)
DE (1) DE602005026852D1 (es)
DK (3) DK1824475T3 (es)
EA (1) EA012299B1 (es)
ES (3) ES2362288T3 (es)
HK (3) HK1109058A1 (es)
HR (3) HRP20110385T1 (es)
HU (2) HUE027197T2 (es)
IL (1) IL183306A (es)
ME (2) ME02306B (es)
MX (1) MX2007006104A (es)
NO (1) NO331831B1 (es)
NZ (1) NZ556038A (es)
PL (3) PL2356987T3 (es)
PT (2) PT1824475E (es)
RS (3) RS54537B1 (es)
SI (3) SI2289509T1 (es)
TW (2) TWI436991B (es)
UA (1) UA88491C2 (es)
WO (1) WO2006053766A1 (es)
ZA (1) ZA200706837B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436991B (zh) * 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007041167A2 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
WO2009099868A1 (en) * 2008-02-06 2009-08-13 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10155708B2 (en) * 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
DK3455213T3 (da) * 2016-05-13 2022-03-07 Symrise Ag Fremgangsmåde til at oprense cannabinoid-forbindelser via simulated moving bed-kromatografi
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) * 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
WO2019046806A1 (en) * 2017-09-01 2019-03-07 Botaniteck Llc SYNTHETIC CANNABIDIOL COMPOSITIONS AND METHODS OF MAKING THE SAME
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
MX2020009335A (es) * 2018-03-07 2020-12-03 Socati Tech Oregon Llc Aislamiento continuo de cannabidiol y conversion de cannabidiol a delta 8-tetrahidro cannabinol y delta 9- tetrahidro cannabinol.
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
CN112292368B (zh) * 2018-06-28 2024-02-02 西姆莱斯有限公司 （+）-大麻素类的合成及其治疗作用
WO2020028198A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
CN113905730A (zh) 2018-10-31 2022-01-07 南迪亚公司 大麻素共晶体的固体组合物
EP3653596A1 (en) 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
BR112022007601A2 (pt) * 2019-10-21 2022-10-04 Esolate Ltd Compostos superfinos e produção dos mesmos
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
AU2021235467A1 (en) 2020-03-12 2021-10-07 Council Of Scientific And Industrial Research Process for the synthesis of cannabidiol and intermediates thereof
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US20020039795A1 (en) 1998-10-26 2002-04-04 Elsohly Et Al Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1409473A2 (en) 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE60321318D1 (de) 2002-02-01 2008-07-10 Resolution Chemicals Ltd Gewinnung von delta-9 tetrahydrocannabinol
WO2003070506A1 (fr) 2002-02-21 2003-08-28 Biel Timothee Dispositif d'entraînement pour vehicules a moteur, notamment avec propulsion hybride
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
AU2004287495A1 (en) 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
CN1997636B (zh) 2004-07-19 2011-09-28 希莱格有限公司 获得纯四氢大麻酚的方法
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI436991B (zh) * 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP2010535238A (ja) 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Also Published As

Publication number Publication date
AU2005305944B2 (en) 2010-03-04
TWI369203B (en) 2012-08-01
NZ556038A (en) 2009-12-24
EP1824475A1 (en) 2007-08-29
DK2289509T3 (en) 2015-11-23
BRPI0519803A2 (pt) 2009-03-17
CY1111471T1 (el) 2015-08-05
JP5048448B2 (ja) 2012-10-17
US20130171259A1 (en) 2013-07-04
CA2587957A1 (en) 2006-05-26
PT1824475E (pt) 2011-06-01
DK2356987T3 (en) 2016-03-21
IL183306A0 (en) 2007-09-20
KR100919719B1 (ko) 2009-10-06
CN101076329B (zh) 2011-08-10
US9675581B2 (en) 2017-06-13
SI1824475T1 (sl) 2011-06-30
JP4995728B2 (ja) 2012-08-08
AR054989A1 (es) 2007-08-01
TW201302722A (zh) 2013-01-16
CN102151259A (zh) 2011-08-17
HUE025904T2 (en) 2016-05-30
US8937097B2 (en) 2015-01-20
WO2006053766A1 (en) 2006-05-26
JP2008101000A (ja) 2008-05-01
NO331831B1 (no) 2012-04-16
TW200633695A (en) 2006-10-01
JP2008520608A (ja) 2008-06-19
WO2006053766A8 (en) 2006-12-14
US20090298930A1 (en) 2009-12-03
CA2921590A1 (en) 2006-05-26
US9744151B2 (en) 2017-08-29
DK1824475T3 (da) 2011-06-06
US20160184260A1 (en) 2016-06-30
CN101076329A (zh) 2007-11-21
EP2356987B1 (en) 2016-01-06
RS54537B1 (en) 2016-06-30
ZA200706837B (en) 2008-04-30
UA88491C2 (ru) 2009-10-26
HUE027197T2 (en) 2016-10-28
AU2005305944A1 (en) 2006-05-26
JP2012180350A (ja) 2012-09-20
PT2289509E (pt) 2015-12-23
AU2010200227A1 (en) 2010-02-11
HRP20160300T1 (hr) 2016-04-22
EP2289509A3 (en) 2011-08-10
HK1109058A1 (en) 2008-05-30
SI2356987T1 (sl) 2016-04-29
ME02403B (me) 2016-09-20
ES2566480T3 (es) 2016-04-13
SI2289509T1 (sl) 2016-01-29
HRP20110385T1 (hr) 2011-06-30
EP1824475B1 (en) 2011-03-09
RS51706B (en) 2011-10-31
HK1154796A1 (en) 2012-05-04
PL2356987T3 (pl) 2016-09-30
EP2356987A1 (en) 2011-08-17
US9278083B2 (en) 2016-03-08
CA2587957C (en) 2016-05-03
US8383842B2 (en) 2013-02-26
NO20072964L (no) 2007-08-17
ES2556802T3 (es) 2016-01-20
RS54338B1 (en) 2016-02-29
EP2289509B1 (en) 2015-10-14
EA200701123A1 (ru) 2007-12-28
EP2289509A2 (en) 2011-03-02
US20160199344A1 (en) 2016-07-14
US20160184261A1 (en) 2016-06-30
ATE500824T1 (de) 2011-03-15
HK1159500A1 (en) 2012-08-03
ES2362288T3 (es) 2011-06-30
TWI436991B (zh) 2014-05-11
HRP20151301T1 (hr) 2016-01-01
IL183306A (en) 2012-06-28
EA012299B1 (ru) 2009-08-28
DE602005026852D1 (de) 2011-04-21
KR20070086529A (ko) 2007-08-27
PL1824475T3 (pl) 2011-09-30
CA2921590C (en) 2019-09-24
PL2289509T3 (pl) 2016-04-29
US20150126596A1 (en) 2015-05-07
ME02306B (me) 2016-06-20

Similar Documents

Publication Publication Date Title
MX2007006104A (es) Metodos para purificar trans-(-)-?9-tetrahidrocanabinol y trans-(+)-?9-tetrahidrocanabinol.
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
WO2004022529A3 (en) Diarylurea derivatives and their use as chloride channel blockers
TW200611695A (en) Pyrrolopyridine derivatives
GB0222495D0 (en) Compounds
HK1065941A1 (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
HK1084404A1 (en) Muteins of tear lipocalin
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
HRP20080175T3 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001014358A3 (en) Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
BRPI0416933A (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente
UA81664C2 (ru) Производные дифенилмочевины и их применение, как блокаторов хлоридных каналов
TW200508208A (en) Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1H-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
TH83573B (th) วิธีการสำหรับการทำให้ทรานส์-(-)- เดลตา9 -เตตราไฮโดรแคนนาบินอล และทรานส์-(+)- เดลตา9 -เตตราไฮโดรแคนนาบินอล บริสุทธิ์
CY1117343T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9-τετραϋδροκανναβινολης
UA86813C2 (ru) Ингибиторы бета-гидроксистероидной дегидрогеназы типа 1
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof

Legal Events

Date Code Title Description
FG Grant or registration